Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma

Sorafenib resistance is one of the major obstacles towards achieving a better outcome in patients with advanced hepatocellular carcinoma (HCC), in which aberrant activation of the hepatocyte growth factor (HGF)/mesenchymal‐epithelial transition pathway is frequently observed. Here, we report that HC...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:FEBS Open Bio
Asıl Yazarlar: Chen, Weibo, Yang, Junsheng, Zhang, Yue, Cai, Huihua, Chen, Xuemin, Sun, Donglin
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2019
Konular:
Research Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6356182/
https://ncbi.nlm.nih.gov/pubmed/30761258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/2211-5463.12578
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller